

1 Utility of Cerebrospinal Fluid Protein Levels as a Potential 2 Predictive Biomarker of Disease Severity in HIV-Associated 3 Cryptococcal Meningitis.

4 John Kasibante¹, Eesha Irfanullah², Abduljewad Wele², Elizabeth Okafor², Kenneth
5 Ssebambulidde¹, Samuel Okurut¹, Enock Kagimu¹, Jane Gakuru¹, Morris K. Rutakingirwa¹,
6 Timothy Mugabi¹, Edwin Nuwagira³, Samuel Jjunju¹, Edward Mpoza¹, Lillian Tugume¹, Laura
7 Nsangi¹, Abdu K Musibire¹, Conrad Muzoora³, Joshua Rhein², David B. Meya^{1,2}, David R.
8 Boulware², Mahsa Abassi²

9 ¹ Infectious Diseases Institute, College of health sciences, Makerere University. P.O. Box 22418,
10 Kampala, Uganda.

11 ² Division of Infectious Diseases & International Medicine, Department of Medicine, University
12 of Minnesota, Minneapolis, MN 55455, USA.

13 ³ Department of Medicine, Mbarara University of Science and Technology, P.O Box 1410,
14 Mbarara, Uganda.

15 **Corresponding author:** John Kasibante, email: johnkasi93@gmail.com, jkasibante@idi.co.ug

16 **Author contributions:** JK conceptualized and developed the initial manuscript draft. EI
17 contributed towards the initial manuscript writing. AW did the statistical analysis. MA, DRB,
18 and DBM mentored JK and EI. All other authors offered comments and edited the manuscript for
19 critical input.

20
21 **Keywords:** HIV; cryptococcal meningitis; cerebral spinal fluid; CSF protein; CSF cytokines;
22 predictive biomarker.

Kasibante CSF Protein in Cryptococcosis

23 **Abstract**

24 **Background.**

25 Cerebrospinal fluid (CSF) protein levels exhibit high variability in HIV-associated cryptococcal
26 meningitis from being normal to markedly elevated. However, the clinical implications of CSF
27 protein levels in cryptococcal meningitis remain unclear.

28 **Methods.**

29 We analysed data from 890 adults with HIV-associated cryptococcal meningitis randomized into
30 two clinical trials in Uganda between 2015 and 2021. CSF protein was grouped into ≥ 100 mg/dL
31 ($n=249$) and <100 mg/dL ($n=641$). We described baseline clinical variables and mortality by
32 CSF protein levels.

33 **Results.**

34 Approximately one-third of individuals had a baseline CSF protein ≥ 100 mg/dL. Those with CSF
35 protein ≥ 100 mg/dL were more likely to present with Glasgow coma scale scores <15 ($P<0.01$),
36 self-reported seizures at baseline ($P=0.02$), higher CD4 T-cells ($p<0.001$), and higher CSF white
37 cells ($p<0.001$). Moreover, those with a baseline CSF protein ≥ 100 mg/dL also had a lower
38 baseline CSF fungal burden ($p<0.001$) and a higher percentage of sterile CSF cultures at day 14
39 ($p=0.02$). Individuals with CSF protein ≥ 100 mg/dL demonstrated a more pronounced immune
40 response consisting of upregulation of immune effector molecules pro-inflammatory cytokines,
41 type-1 T-helper cell cytokines, type-3 chemokines, and immune-exhaustion marker ($p<0.05$). 18-
42 week mortality risk in individuals with a CSF protein <100 mg/dL was 34% higher, (unadjusted
43 Hazard Ratio 1.34; 95% CI, 1.05 to 1.70; $p=0.02$) than those with ≥ 100 mg/dL.

Kasibante CSF Protein in Cryptococcosis

44 **Conclusion.**

45 In cryptococcal meningitis, individuals with CSF protein ≥ 100 mg/dL more frequently presented
46 with seizures, altered mental status, immune activation, and favourable fungal outcomes.
47 Baseline CSF protein levels may serve as a surrogate marker of immune activation and
48 prognosis.

49 **Background.**

50 Sub-Saharan Africa is home to an estimated 20.1 million of the 38.4 million people living
51 with HIV (PLWH) globally [1]. Since 2010, increased access to HIV testing, antiretroviral
52 therapy (ART), and improved management of opportunistic infections has decreased HIV-
53 associated mortality by 47% [1]. Despite advancements in HIV care and management, HIV-
54 associated opportunistic infections remain a significant burden in sub-Saharan Africa, where
55 54% of cryptococcal meningitis and 63% of all cryptococcal-related mortality occur [2].
56 Cryptococcal meningitis mortality, even in the setting of clinical trials, remains unacceptably
57 high, with 10-week mortality exceeding 25% [3, 4]. Therefore, there is a need to identify and
58 understand the role of predictive biomarkers of cryptococcal meningitis severity to inform
59 targeted interventions and improve outcomes.

60 Cerebrospinal fluid (CSF) proteins are characterized by marked intra-individual and
61 inter-individual variability in healthy individuals with approximately 80% of protein originating
62 from blood and 20% from the central nervous system [5]. Elevated CSF protein therefore
63 indicates either a dysfunction in the blood-CSF or the blood-brain barrier [6]. In healthy
64 individuals, CSF protein levels range between 15 and 60 mg/dL. In cryptococcal meningitis, CSF
65 protein levels are highly variable, ranging from normal levels to as high as >20 times the upper
66 limit of normal [6, 7]. In 1974, Diamond and Bennet found that in cryptococcal meningitis,
67 baseline CSF protein levels were higher in persons who survived compared to those who died
68 [8]. In two recent small retrospective studies, individuals with cryptococcal meningitis and high
69 baseline CSF protein had a better response to antifungal therapy and improvement in clinical
70 symptoms compared to those with lower baseline CSF protein levels [7, 9]. While existing data

Kasibante CSF Protein in Cryptococcosis

71 offers intriguing insights into the relationship between baseline CSF protein levels and outcomes
72 in cryptococcal meningitis, it is crucial to acknowledge that the current evidence remains limited
73 and inconclusive.

74 Our study aims to enhance our understanding of the role of CSF protein in cryptococcal
75 meningitis and to assesses its potential as a predictive biomarker of severity in HIV-associated
76 cryptococcal meningitis. Additionally, we sought to investigate the relationship between CSF
77 protein levels with established risk factors of severe disease, such as seizures, altered mental
78 status, CD4 T-cell count, CSF fungal burden, CSF opening pressure, and CSF cytokine profile
79 [10-12]. Furthermore, we examined the predictive value of elevated CSF protein as a predictor of
80 mortality.

81 **Methods**

82 **Study Design**

83 We carried out a prospective cohort study of Ugandans adults diagnosed with HIV-
84 associated cryptococcal meningitis as a secondary analysis of two randomized clinical trials: (i)
85 the Adjunctive Sertraline for the Treatment of HIV-associated Cryptococcal Meningitis
86 (ASTRO-cm) trial enrolled from March 9, 2015, to May 29, 2017; and (ii) the AMBIsome
87 Therapy Induction Optimisation (AMBITION-cm) trial enrolled from January 2018 through
88 February 2021 [3, 4]. A detailed description of the study design for each clinical trial is
89 published elsewhere [4, 13]. In brief, the ASTRO-cm trial investigated the impact of adjunctive
90 sertraline on cryptococcal meningitis treatment outcomes. The AMBITION-cm trial investigated
91 the efficacy of single high-dose liposomal amphotericin B on fluconazole and flucytosine

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Kasibante CSF Protein in Cryptococcosis

92 backbone in cryptococcal meningitis. Participants were recruited and enrolled at Mulago
93 National Specialist Hospital, Kiruddu National Referral Hospital, and Mbarara Regional Referral
94 Hospital in Uganda. All participants diagnosed with a first episode of HIV-associated
95 cryptococcal meningitis by a positive finger stick and CSF cryptococcal antigen (CrAg) were
96 included in this analysis [14, 15]. All study participants had a diagnostic LP performed at
97 baseline. CSF samples were collected and sent to the laboratory and analysed for CSF cell
98 counts, quantitative fungal cultures, and protein concentration.

99 Ethical approvals for both clinical trials were granted from the Mulago Hospital Research
100 and Ethics Committee, the Uganda National Council of Science & Technology, and the
101 University of Minnesota Institutional Review Board. All participants or their surrogate provided
102 their written consent for study participation.

103 **Cytokine quantification**

104 We assessed CSF cytokine and chemokine concentrations at baseline among a subset of
105 the ASTRO-CM study participants. CSF samples were centrifuged at 400g for 4 minutes at 4°C,
106 supernatant was collected and stored at -80°C. Frozen samples were transported to the University
107 of Minnesota and cytokines/chemokines were measured using the Human Luminex Discovery
108 Assay (R&D systems, Minneapolis, MN, USA). The 43 cytokine and chemokine assay included
109 **mediators of inflammatory response**: interleukin (IL) -1a, IL-1b, IL-6, platelet derived growth
110 factor (PDGF)-AA, PDGF-AB, and vascular endothelial growth factor (VEGF); **type-1 T helper**
111 **cell (Th1) associated cytokines**: macrophage inflammatory protein (MIP)1a/CCL3,
112 MIP1b/CCL4, RANTES/CCL5, tumor necrosis factor (TNF)- α , IL-12, IL-15, interferon (IFN)-
113 γ , interferon-inducible protein (IP)-10/CXCL10, granulocyte-macrophage colony stimulating

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Kasibante CSF Protein in Cryptococcosis

114 factor (GM-CSF), and granzyme B; **Th2 cytokines**: IL-4, IL-5, IL-13, IL-25, IL-33, and eotaxin;
115 **Th3 cytokines**: MIP3a/CCL20, growth-related oncogene (GRO)- α /CXCL1, GRO- β /CXCL2,
116 CXCL8/IL-8, IL-17A, and granulocyte colony stimulating factor (G-CSF); **modulators of**
117 **immune response**: IL-10, IL-1 receptor antagonist (IL-1ra), Endothelial growth factor (EGF),
118 and transforming growth factor (TGF)- α ; **immune exhaustion**: programmed death ligand-1 (PD-
119 L1), **Type-1 interferon- α** and interferon- β , and **non-classified chemokines**: MIP3b/CCL19, IL-
120 3, CD40 ligand/TNFSF5, fractalkine/CX3CL1, Flt3 ligand,

121 **Statistical methods**

122 We initially divided patients into tertiles: low CSF protein (0 to < 45 mg/dL), middle
123 CSF protein (≥ 45 mg/dL to <100 mg/dL), and high CSF protein (≥ 100 mg/dL). We found no
124 significant difference between the low and middle tertile groups in terms of survival, and
125 therefore we combined them into an aggregate CSF protein group of <100 mg/dL. We
126 summarized baseline demographic variables and laboratory parameters by CSF protein <100
127 mg/dL vs. CSF protein ≥ 100 mg/dL. We also evaluated the impact of ART status at enrollment
128 on CSF protein levels and its contribution to clinical presentation and outcomes given the role
129 that ART plays in unmasking immune reconstitution inflammatory syndrome (IRIS). Data are
130 presented as median with interquartile range (IQR) or proportions with statistical testing via
131 Kruskal-Wallis's test for medians and Fisher's exact tests for proportions. P values <0.05 were
132 considered statistically significant. We adjusted cytokine P-values with the Benjamini-Hochberg
133 procedure to control the false discovery rate [16]. We compared survival by Kaplan-Meier
134 curves and Cox proportion hazard regression analysis using both the adjusted and unadjusted
135 models. The adjusted survival model included differentially distributed co-variables between
136 groups, including CSF opening pressure >250 mmH₂O, CSF white cell count, seizures, and CSF

Kasibante CSF Protein in Cryptococcosis

137 cryptococcal quantitative colony forming units (CFUs). Quantitative CFUs were \log_{10}
138 transformed for normalization. We conducted all analyses with SAS version 9.4 (SAS Institute,
139 Cary, NC).

140 **Results**

141 **Demographics**

142 We included 890 adults with HIV-associated cryptococcal meningitis in our analysis.
143 72% (641/890) had CSF protein levels <100 mg/dL at baseline. We found no statistically
144 significant differences in age, gender, and weight at baseline between CSF protein groups “Table
145 1”. While there was no difference between the percentage of persons who were on ART ($p=0.82$)
146 or the duration of time on ART ($p=0.05$) at baseline, we found a statistically significant higher
147 CD4 T-cell count in persons with CSF protein ≥ 100 mg/dL (median CD4 = 28, IQR 10 to 65
148 cells/ μ L) as compared to persons with CSF protein <100 mg/dL (median CD4 = 15, IQR 6 to 41
149 cells/ μ L; $p<0.001$). Individuals with CSF protein ≥ 100 mg/dL presented with more self-reported
150 seizures ($p=0.02$) and a Glasgow Coma Scale score <15 ($p<0.01$) compared to those with CSF
151 protein <100 mg/dL.

152

Kasibante CSF Protein in Cryptococcosis

153 **Table 1. Clinical Parameters and Treatment Outcomes by Baseline CSF**
 154 **Protein Levels**
 155

| | N | CSF Protein <100 mg/dL (N = 641) | N | CSF Protein ≥100mg/dL (N = 249) | P-value ¹ |
|----------------------------------------------------------|-----|----------------------------------------|-----|---------------------------------------|----------------------|
| Age (years) | 641 | 35 [30, 40] | 249 | 35 [30, 42] | 0.46 |
| Female | 641 | 264 (41) | 249 | 87 (35) | 0.09 |
| Weight (kg) | 561 | 50 [46, 60] | 224 | 53 [47, 60] | 0.26 |
| Antiretroviral Therapy (ART) Status | | | | | |
| Currently on ART | 640 | 307 (48) | 249 | 117 (47) | 0.82 |
| Months on ART | 306 | 4 [1, 32] | 115 | 3 [1, 13] | 0.05 |
| ≤14 Days | 306 | 51 (17) | 115 | 26 (23) | 0.10 |
| 15-30 Days | | 37 (12) | | 11 (10) | |
| 31-90 Days | | 45 (15) | | 25 (22) | |
| >90 Days | | 173 (57) | | 53 (46) | |
| Clinical | | | | | |
| Seizures | 641 | 92 (14) | 249 | 52 (21) | 0.02 |
| Glasgow Coma Scale <15 | 640 | 231 (36) | 249 | 114 (46) | <0.01 |
| CD4 <50 cells/mm ³ categorical | 614 | 485 (79) | 240 | 158 (66) | <0.001 |
| CD4 cells/mm ³ | 614 | 15 [6, 41] | 240 | 28 [10, 65] | <0.001 |
| CSF Opening Pressure mmH₂O | | | | | |
| Baseline | 590 | 259 [170, 390] | 234 | 255 [170, 350] | 0.22 |
| Day 3 | 149 | 300 [196, 420] | 54 | 290 [210, 400] | 0.77 |
| Day 7 | 292 | 180 [110, 280] | 119 | 180 [100, 268] | 0.34 |
| Day 14 | 223 | 210 [130, 295] | 98 | 157[100, 240] | <0.01 |
| Quantitative CSF Culture, log₁₀ CFU/mL | | | | | |
| Baseline | 622 | 4.68 [3.2, 5.5] | 247 | 4.09 [2.3, 5.3] | <0.001 |
| Day 3 | 156 | 4.45 [3.1, 5.2] | 60 | 3.48 [2.2, 4.9] | 0.04 |
| Day 7 | 313 | 1.91 [0.0, 3.6] | 131 | 0.00 [0.0, 2.8] | <0.01 |
| Day 14 | 245 | 0.00 [0.0, 1.7] | 102 | 0.00 [0.0, 1.2] | 0.38 |
| CSF White Cell cells/mm³ | | | | | |
| CSF <5 white cells/mm ³ | 636 | 460 (72) | 246 | 77 (31) | <0.001 |
| Baseline | 636 | <5 [<5, 10] | 246 | 53 [<5, 150] | <0.001 |
| Day 3 | 159 | <5 [<5, 30] | 60 | 28 [<5, 138] | <0.001 |
| Day 7 | 312 | <5 [<5, 45] | 130 | 35 [<5, 95] | <0.001 |
| Day 14 | 248 | <5 [<5, 25] | 103 | 25 [<5, 65] | <0.001 |
| CSF Sterility status | | | | | |
| Baseline Sterile Culture | 622 | 47 (8) | 247 | 28 (11) | 0.08 |
| Day 14 Sterile Culture | 429 | 191 (45) | 149 | 83 (56) | 0.02 |
| Early Fungicidal Activity, log ₁₀ CFU/mL/d | 474 | 0.333 (0.186, 0.480) | 191 | 0.326 (0.208, 0.482) | 0.43 |

Data are represented as Median [IQR] or N (%)

¹Kruskal-Wallis test for medians; Fisher Exact tests for proportions

Day 3, 7, and 14 values are collected within +/-1 day within the visit window

Kasibante CSF Protein in Cryptococcosis

157 **CSF characteristics**

158 Baseline CSF white cells were significantly higher in individuals with CSF protein ≥ 100
159 mg/dL (median 53, IQR <5 to 150 white cells/mm³ CSF) compared to those with CSF protein
160 <100 mg/dL (median <5, IQR <5 to 10 white cells/mm³ CSF; $p < 0.001$). CSF white cell counts
161 remained significantly higher through days 3, 7, and 14 among individuals with CSF protein
162 ≥ 100 mg/dL as compared to CSF protein <100 mg/dL ($p < .001$). Baseline CSF quantitative
163 cryptococcal cultures were significantly lower in persons with CSF protein ≥ 100 mg/dL (median
164 12 300, IQR 200 to 200 000 CFU/mL) compared to persons with CSF protein <100 mg/dL
165 (median 48 000, IQR 1585 to 316 000 CFU/mL; $p < 0.001$). At day 14, the proportion of persons
166 with a sterile CSF culture was higher in those with CSF protein ≥ 100 mg/dL compared to those
167 with CSF protein <100 mg/dL (CSF protein ≥ 100 mg/dL 56% (83/149) vs. CSF protein <100
168 mg/dL 45% (191/429); $p = 0.02$). We found no differences in baseline CSF opening pressure
169 between individuals with CSF protein ≥ 100 mg/dL compared to CSF protein <100 mg/dL
170 ($p = 0.22$).

171 CSF cytokine assays revealed that individuals with CSF protein ≥ 100 mg/dL had
172 significantly higher levels of pro-inflammatory cytokines, interleukin(IL)-1 β , IL-6, PDGF-AA
173 and VEGF; type-1 T helper cell (Th1) response cytokines IL-12, IL-15, interferon- γ , TNF- α , and
174 GM-CSF; effector molecules granzyme B and TRAIL; type-2 T helper cell (Th2) response
175 cytokine IL-5 and Eotaxin; type 3/ Th17 related cytokines IL-17, G-CSF, CXCL1, CXCL2,
176 CXCL8, and CCL20; and immune exhaustion marker PD-L1; as compared to those with CSF
177 protein <100 mg/dL “Table 2”.

178

Kasibante CSF Protein in Cryptococcosis

179 **Table 2: Baseline CSF Cytokines and Chemokines by Baseline CSF Protein**
180 **Levels**

| CSF Biomarker, pg/mL (log2) | N | CSF Protein < 100 mg/dL Median (IQR) | N | CSF Protein ≥ 100 mg/dL Median (IQR) | P-value* | P-value** |
|--------------------------------------------------------------------------------------------------------------------------------|-----|-----------------------------------------|----|-----------------------------------------|----------|---------------|
| Mediate inflammatory responses | | | | | | |
| IL-1a | 229 | 3.8 [1.4, 6.8] | 84 | 5.4 [2.8, 7.6] | 0.0701 | 0.1018 |
| IL-6 | 229 | 116 [36.7, 733] | 84 | 380 [119, 2343] | 0.0004 | 0.0045 |
| IL-1b | 229 | 2.4 [1.0, 3.8] | 84 | 3.3 [1.9, 5.7] | 0.0011 | 0.0062 |
| PDGF-AA | 228 | 81.8 [48.8, 117] | 84 | 99.8 [57.6, 174] | 0.0069 | 0.0141 |
| PDGF-AB | 229 | 2.6 [0.4, 4.3] | 84 | 3.6 [0.8, 5.2] | 0.1109 | 0.1426 |
| VEGF | 229 | 44.9 [28.7, 75.5] | 84 | 59.8 [31.9, 100.0] | 0.0166 | 0.0311 |
| FGF Basic | 229 | 1.5 [0.3, 1.5] | 84 | 1.5 [0.3, 5.0] | 0.0892 | 0.1181 |
| Type 1 T helper cell (Th₁) immune response, ideal for effective intracellular killing of <i>Cryptococcus</i> | | | | | | |
| IL-12 | 229 | 5.2 [0.8, 10.0] | 84 | 8.0 [3.6, 13.2] | 0.0058 | 0.0131 |
| IL-15 | 229 | 3.5 [2.4, 5.1] | 84 | 3.4 [2.5, 5.0] | 0.8414 | 0.8414 |
| Interferon-γ | 229 | 4.2 [0.4, 9.5] | 84 | 8.3 [1.5, 16.9] | 0.0018 | 0.0062 |
| TNF-α | 229 | 40.8 [16.1, 90.9] | 84 | 64.3 [29.3, 142.4] | 0.0046 | 0.0115 |
| GM-CSF | 229 | 33.7 [22.5, 54.7] | 84 | 46.4 [26.8, 81.5] | 0.0033 | 0.0099 |
| Granzyme B | 229 | 12.3 [3.5, 21.8] | 84 | 21.1 [11.5, 82.1] | 0.0000 | 0.0000 |
| TRAIL | 229 | 7.0 [2.5, 12.3] | 84 | 10.9 [4.8, 14.9] | 0.0017 | 0.0064 |
| MCP1/CCL2 | 229 | 831 [497, 2207] | 84 | 998 [578, 2265] | 0.4399 | 0.4828 |
| MIP1a/CCL3 | 229 | 36.6 [20.4, 66.5] | 84 | 50.6 [29.7, 78.2] | 0.0418 | 0.0672 |
| MIP1b/CCL4 | 229 | 166 [109, 247] | 84 | 190 [121, 305] | 0.0599 | 0.0899 |
| Rantes/CCL5 | 137 | 40.8 [4.1, 99.1] | 58 | 73.3 [4.1, 143.7] | 0.3302 | 0.3715 |
| IP10/CXCL10 | 229 | 2336 [1027, 2900] | 84 | 2568 [1400, 3139] | 0.1525 | 0.1855 |
| Type 2 T helper cell (Th₂) immune response, not protective against <i>Cryptococcus</i> | | | | | | |
| IL-4 | 229 | 1.6 [0.7, 2.6] | 84 | 1.5 [0.6, 2.3] | 0.6020 | 0.6300 |
| IL-5 | 229 | 0.9 [<0.1, 3.2] | 84 | 2.8 [0.2, 4.7] | 0.0001 | 0.0023 |
| IL-13 | 229 | 22.3 [13.7, 34.5] | 84 | 29.3 [14.5, 38.9] | 0.1326 | 0.1658 |
| IL-33 | 229 | 7.6 [2.0, 13.1] | 84 | 10.1 [3.6, 17.1] | 0.0762 | 0.1039 |
| IL-25 | 229 | 17.0 [4.9, 34.9] | 84 | 17.7 [7.4, 31.9] | 0.7725 | 0.7901 |
| Eotaxin | 229 | 14.5 [9.2, 19.9] | 84 | 18.2 [11.1, 23.1] | 0.0084 | 0.0164 |
| Type 3 immune response, involves neutrophils mediated inflammation | | | | | | |
| IL-17A | 229 | 2.0 [0.2, 4.4] | 84 | 3.9 [0.9, 7.7] | 0.0006 | 0.0045 |
| GCSF | 229 | 30.9 [13.2, 68.3] | 84 | 45.4 [18.6, 108.2] | 0.0222 | 0.0400 |
| GROa/CXCL1 | 229 | 144.5 [57.5, 435] | 84 | 362 [95.1, 667] | 0.0005 | 0.0045 |
| GROb/CXCL2 | 229 | 15.2 [6.6, 25.9] | 84 | 19.8 [8.5, 43.0] | 0.0054 | 0.0128 |
| IL8/CXCL8 | 228 | 289 [119, 814] | 84 | 584 [269, 1777] | 0.0009 | 0.0058 |
| MIP3a/CCL20 | 229 | 4.5 [1.3, 8.4] | 84 | 6.9 [3.2, 10.5] | 0.0017 | 0.0070 |
| Modulate/dampen all 3 types of immune responses | | | | | | |
| IL-1ra | 228 | 4199 [1271, >10000] | 84 | 7237 [3590, >10000] | 0.0012 | 0.0060 |
| IL-10 | 229 | 229 [155, 332] | 84 | 263 [176, 393] | 0.0524 | 0.0813 |

Kasibante CSF Protein in Cryptococcosis

| | | | | | | |
|-------------------------------------------------------------------------------------------------------------------|-----|----------------------|----|----------------------|--------|---------------|
| IL-2 | 229 | 4.7 [2.3, 8.3] | 84 | 7.1 [3.3, 10.8] | 0.0035 | 0.0098 |
| TGF- α | 229 | 9.3 [5.4, 15.1] | 84 | 11.5 [5.6, 20.4] | 0.0384 | 0.0640 |
| EGF | 229 | 1.3 [0.6, 6.0] | 84 | 3.2 [0.6, 7.7] | 0.1937 | 0.2294 |
| Immune exhaustion (with HIV and cryptococcal chronic infections) | | | | | | |
| PDL-1 | 229 | 97.9 [51.0, 166.9] | 84 | 161.5 [67.8, 265.5] | 0.0004 | 0.0060 |
| With G-CSF, GM-CSF, stimulate production of immune cells in the bone marrow | | | | | | |
| IL-3 | 229 | 4.6 [0.7, 15.0] | 84 | 7.1 [0.7, 17.4] | 0.2022 | 0.2333 |
| Other cytokines | | | | | | |
| MIP3b/CCL19 | 229 | 81.6 [34.4, 175.5] | 84 | 146.4 [50.3, 273.3] | 0.0037 | 0.0098 |
| TNFSF5/CD40-L | 229 | 384 [65.2, 636] | 84 | 529 [251, 835] | 0.0025 | 0.0080 |
| Fractalkine/CX3CL1 | 229 | 292.0 [174.3, 444.5] | 84 | 383.1 [240.6, 596.2] | 0.0015 | 0.0068 |
| Flt-3Ligand | 229 | 97.3 [64.0, 141.1] | 84 | 122.5 [81.4, 171.0] | 0.0062 | 0.0133 |
| Type 1 Interferons, generally for anti-viral responses and down regulates Th₁ immune responses. | | | | | | |
| Interferon- α | 229 | 4.3 [1.9, 9.4] | 84 | 5.5 [3.0, 9.7] | 0.0748 | 0.1052 |
| Interferon- β | 229 | 0.3 [0.1, 2.0] | 84 | 1.1 [0.2, 2.6] | 0.0277 | 0.0479 |

*P-values from Wilcoxon test.

**Adjusted P value by Benjamini Hochberg procedure to control false discovery rate.

Abbreviations: MIP, Macrophage inflammatory protein; TNF, tumor necrosis factor; GRO, growth-related oncogene; IL-interleukin; IL-1ra, interleukin-1 receptor antagonist; IFN, Interferon; IP-10, interferon-inducible protein; G-CSF, granulocyte colony stimulating factor; GM-CSF, granulocyte-macrophage colony stimulating factor; PDL-1, programmed death ligand-1; EGF, Endothelial growth factor; TGF, transforming growth factor; PDGF, platelet derived growth factor; VEGF, vascular endothelial growth factor.

181

182 **Effect of ART on CSF Protein Levels**

183 ART status at study enrolment influenced clinical parameters in both CSF protein

184 categories “Table 3”. Individuals on ART and with a baseline CSF protein ≥ 100 mg/dL were

185 more likely to present with a Glasgow coma scale score < 15 as compared to persons on ART and

186 with a baseline CSF protein < 100 mg/dL (98/307 vs. 50/117, $p < 0.04$). There was no difference in

187 Glasgow coma scale score < 15 between CSF protein groups in individuals who were not

188 receiving ART on admission ($p = 0.10$). Persons with a baseline CSF protein ≥ 100 mg/dL had a

189 higher CD4 T-cell count, higher CSF white cell count at baseline and through day 14, and a

190 lower baseline CSF fungal burden compared to persons with CSF protein < 100 mg/dL,

191 irrespective of baseline ART status. Individuals on ART with a CSF protein ≥ 100 mg/dL had a

192 higher percentage of sterile cultures at day 14 compared to individuals on ART and with a CSF

Kasibante CSF Protein in Cryptococcosis

193 protein <100 mg/dL (p<0.01). There was no difference in the percentage of day 14 sterile
 194 cultures between CSF protein groups in those who were not on ART at baseline (p=0.78).

195 **Table 3: Clinical Presentation and Outcomes by Baseline CSF Protein Levels**
 196 **and ART Status**

| | Receiving Antiretroviral therapy at Baseline | | | | | NOT Receiving Antiretroviral therapy | | | | |
|---------------------------------------------|----------------------------------------------|---------------------------------|-----|--------------------------------|----------------------|--------------------------------------|---------------------------------|-----|--------------------------------|----------------------|
| | N | CSF protein < 100 mg/dL (N=307) | N | CSF protein ≥ 100mg/dL (N=117) | P-value ¹ | N | CSF protein < 100 mg/dL (N=333) | N | CSF protein ≥ 100mg/dL (N=132) | P-value ¹ |
| Demographics | | | | | | | | | | |
| Age, years | 307 | 35 [30, 40] | 117 | 35 [30, 42] | 0.35 | 333 | 35 [30, 41] | 132 | 35 [30, 42] | 0.90 |
| Female | 307 | 134 (44%) | 117 | 41 (35%) | 0.12 | 333 | 130 (39%) | 132 | 46 (35%) | 0.46 |
| Weight, kg | 278 | 50 [46, 58] | 107 | 52 [46, 59] | 0.52 | 283 | 51 [47, 60] | 117 | 54 [48, 60] | 0.40 |
| Clinical | | | | | | | | | | |
| Seizures | 307 | 37 (12%) | 117 | 21 (18%) | 0.12 | 333 | 55 (17%) | 132 | 31 (24%) | 0.09 |
| Glasgow Coma scale<15 | 307 | 98 (32%) | 117 | 50 (43%) | 0.04 | 332 | 132 (40%) | 132 | 64 (49%) | 0.10 |
| CD4<50 cells/mm ³ | 294 | 217 (74%) | 112 | 59 (53%) | <0.01 | 319 | 267 (84%) | 128 | 99 (77%) | 0.13 |
| CD4, cells/mm ³ | 294 | 20 [8, 52] | 112 | 42 [16, 88] | <0.01 | 319 | 13 [6, 33] | 128 | 19 [8, 45] | <0.01 |
| Opening Pressure, mmH₂O | | | | | | | | | | |
| Baseline | 282 | 245 [170, 370] | 108 | 260 [180, 350] | 0.99 | 307 | 270 [170, 400] | 126 | 250 [160,340] | 0.10 |
| Day 3 | 67 | 286 [190, 395] | 27 | 268 [180, 400] | 0.94 | 81 | 320 [200, 450] | 27 | 304 [210,401] | 0.69 |
| Day 7 | 136 | 180 [120, 262] | 57 | 180 [110, 248] | 0.52 | 156 | 190 [106, 293] | 62 | 185 [90, 280] | 0.46 |
| Day 14 | 106 | 200 [120, 290] | 39 | 150 [100, 240] | 0.07 | 117 | 230 [140, 300] | 59 | 160 [90, 240] | 0.01 |
| CSF Culture, log₁₀ CFU/mL | | | | | | | | | | |
| Baseline | 299 | 4 [2.5, 5.2] | 116 | 3 [1.6, 4.6] | <0.01 | 322 | 5 [3.9, 5.6] | 131 | 5 [3.3, 5.5] | 0.04 |
| Day 3 | 73 | 4 [1.6, 5.0] | 31 | 3 [1.5, 4.7] | 0.36 | 82 | 5 [4.0, 5.3] | 29 | 4 [2.4, 5.0] | 0.06 |
| Day 7 | 146 | 2 [0.0, 3.3] | 64 | 0 [0.0, 2.1] | <0.01 | 167 | 2 [0.0, 3.7] | 67 | 1 [0.0, 3.2] | 0.18 |
| Day 14 | 116 | 0 [0.0, 1.6] | 40 | 0 [0.0, 1.0] | 0.51 | 129 | 0 [0.0, 2.1] | 62 | 0 [0.0, 1.4] | 0.47 |
| CSF White cells/mm³ | | | | | | | | | | |
| CSF <5 white cells/mm ³ | 304 | 214 (70%) | 115 | 29 (25%) | <0.01 | 331 | 246 (74%) | 131 | 48 (37%) | <0.01 |
| Baseline | 304 | <5 [<5, 18] | 115 | 70 [<5, 205] | <0.01 | 331 | <5 [<5, 5] | 131 | 40 [<5, 140] | <0.01 |
| Day 3 | 73 | <5 [<5, 35] | 31 | 30 [<5, 120] | <0.01 | 85 | <5 [<5, 25] | 29 | 25 [<5, 240] | <0.01 |
| Day 7 | 146 | <5 [<5, 35] | 63 | 40 [<5, 85] | <0.01 | 166 | <5 [<5, 50] | 67 | 30 [<5, 115] | <0.01 |
| Day 14 | 117 | <5 [<5, 30] | 41 | <5 [<5, 65] | 0.04 | 131 | <5 [<5, <5] | 62 | 28 [<5, 65] | <0.01 |
| CSF sterility | | | | | | | | | | |
| Baseline | 299 | 34 (11%) | 116 | 19 (16%) | 0.19 | 322 | 13 (4%) | 131 | 9 (7%) | 0.23 |
| Day 14 | 212 | 101 (48%) | 78 | 52 (67%) | <0.01 | 216 | 89 (41%) | 71 | 31 (44%) | 0.78 |
| Mortality | | | | | | | | | | |
| 2 Weeks | 307 | 74 (24%) | 117 | 22 (19%) | 0.30 | 333 | 84 (25%) | 132 | 27 (21%) | 0.33 |
| 18 Weeks | 307 | 127 (41%) | 117 | 42 (36%) | 0.32 | 333 | 150 (45%) | 132 | 44 (33%) | 0.02 |

Data are represented as Median [IQR] or N (%)

¹Kruskal-Wallis test for medians; Fisher Exact tests for proportions

Day 3, 7, and 14 values are collected within +/-1 day within the visit window

197

198 Outcomes

199 CSF protein levels influenced survival outcomes. Through 18 weeks, those with a CSF
 200 protein <100 mg/dL were at a 34% higher risk of death compared to individuals with CSF
 201 protein ≥100 mg/dl (Hazard Ratio=1.34; 95% CI 1.05 to 1.70; p=0.02) “Table 4, Fig 1a”.

Kasibante CSF Protein in Cryptococcosis

202 Adjustment for baseline CSF fungal burden, Glasgow coma scale score <15, CSF white count,
203 CSF opening pressure, and baseline self-reported seizures, attenuated the 18-week mortality risk
204 between CSF protein groups (adjusted Hazard Ratio = 1.24; 95%CI, 0.94 to 1.64; p=0.13).
205 Mortality rates through 18-weeks differed by ART status. Mortality was highest among
206 individuals who were not on ART and had a baseline CSF protein <100 mg/dL (150/333)
207 compared to CSF protein ≥100 mg/dL (44/132) (p=0.02), while mortality through 18-weeks was
208 similar in individuals on ART and CSF protein (44/132) (p=0.02) “Fig 1b”.

209 **Table 4. Mortality by Baseline CSF Protein Levels**

| | | CSF Protein < 100 mg/dL | CSF Protein ≥ 100 mg/dL | P-value |
|-------------------------------|-----------------------|----------------------------|----------------------------|-------------|
| Deaths within 2 Weeks | No. Patients | 641 | 249 | |
| | No. (%) with Event | 159 (25) | 49 (20) | |
| | Hazard Ratio (95% CI) | | | |
| | Unadjusted | 1.30 (0.95 - 1.80) | REF | 0.10 |
| | Adjusted ¹ | 1.15 (0.80 - 1.67) | REF | 0.45 |
| Deaths within 18 Weeks | No. Patients | 641 | 249 | |
| | No. (%) with Event | 278 (43) | 86 (35) | |
| | Hazard Ratio (95% CI) | | | |
| | Unadjusted | 1.34 (1.05 - 1.70) | REF | 0.02 |
| | Adjusted ¹ | 1.24 (0.94 - 1.64) | REF | 0.13 |

¹ Adjusted for Baseline CSF quantitative culture log₁₀ CFU/mL, Glasgow Coma Scale, CSF White Cell, Baseline Opening Pressure, and Seizures

210

211 **Figure 1. Kaplan- Meier curves of 18-week survival by baseline CSF protein**
212 **levels alone (1a) and by baseline CSF protein levels and ART status (1b).**

213

214 **Discussion**

215 We demonstrate that in cryptococcal meningitis, persons presenting with CSF protein
216 ≥100 mg/dL had better overall 18-week survival and more frequently presented with altered
217 mental status, seizures, higher CSF white cell count, and a lower CSF quantitative cryptococcal

Kasibante CSF Protein in Cryptococcosis

218 culture. When stratified by ART status, only individuals receiving ART and a CSF protein ≥ 100
219 mg/dL presented more frequently with altered mental status. Furthermore, CSF protein ≥ 100
220 mg/dL was associated with higher levels of CSF pro-inflammatory, type-1, and type-3 cytokine
221 response. We found a 34% increased hazard of 18-week mortality among individuals with a
222 baseline CSF protein < 100 mg/dL as compared to those with CSF protein ≥ 100 mg/dL. After
223 adjusting for CSF fungal burden, Glasgow coma scale score < 15 , CSF white cell count, CSF
224 opening pressure, and baseline self-reported seizures, the 18-week mortality difference was only
225 partially attenuated with a remaining 24% increased hazard in mortality that was not statistically
226 different but unexplained by traditional risk factors. Taken together, these findings suggest that
227 CSF protein is a possible predictive biomarker of cryptococcal meningitis severity that is easily
228 accessible at baseline unlike quantitative CSF fungal cultures, which take 7 or more days and are
229 not performed in most routine clinical care settings.

230 In cryptococcal meningitis, high baseline CSF fungal burden and slow rate of fungal
231 clearance are independent predictors of increased mortality at 2 and 10 weeks [10, 12, 17].
232 Baseline CSF fungal burden and rate of fungal clearance are influenced by the degree of cell-
233 mediated immunity and host inflammatory response in cryptococcal meningitis [18]. Higher
234 CD4 T-cell count, CSF white cell count, and CSF pro-inflammatory cytokines, IL-6, interferon-
235 γ , and TNF- α , are associated with a lower CSF fungal burden, a more rapid rate of fungal
236 clearance, and improved survival [11, 18-20]. We found that individuals with a baseline CSF
237 protein ≥ 100 mg/dL presented with a higher CD4 T-cell count and a higher CSF white blood cell
238 count, suggesting the presence of a robust inflammatory response compared to those with a CSF
239 protein < 100 mg/dL, even in the absence of ART.

Kasibante CSF Protein in Cryptococcosis

240 In murine models of *Cryptococcus neoformans* infection, recruitment of CD4⁺ and CD8⁺
241 leukocytes coincided with CSF cytokine production, white cell recruitment and fungal clearance
242 [21]. In the current study, individuals with CSF protein ≥ 100 mg/dL exhibited a predominantly
243 pro-inflammatory cytokine response skewed towards type-1 and type-3 T helper cell immune
244 responses. These individuals also exhibited higher levels of some type-2 T helper cell and
245 immune-modulatory cytokines; but this was to a lesser extent (<50% of cytokines in these
246 categories were statistically significant). The elevated levels of chemokines, CXCL1, CXCL2,
247 CXCL8, and CCL20, responsible for T cells, B cells, dendritic cells, monocytes, and neutrophils
248 recruitment, would explain the higher CSF white cell count observed in those with CSF protein
249 ≥ 100 mg/dL [11, 18, 20, 22-25]. Moreover, we noted increased expression of the immuno-
250 regulatory cytokines, IL-1ra and IL-2, and the immune exhaustion protein PD-L1, which
251 suppress activated T-cells, in those with CSF protein ≥ 100 mg/dL, suggesting a possible
252 attenuation of damaging inflammatory effects of activated T-cells [21, 26-28]. The combination
253 of this cytokine and cellular response, along with the anti-cryptococcal activity of Granzyme B,
254 likely explains the lower baseline CSF fungal burden and a higher percentage of sterile CSF
255 cultures at day 14 among individuals with CSF protein ≥ 100 mg/dL [18, 29, 30].

256 Cell-mediated immunity plays a crucial role in protecting against the development of
257 cryptococcal disease and promoting fungal clearance [21, 31]. Deficiency in CD4 T-cells
258 increases the susceptibility to cryptococcal meningitis and is associated with cryptococcal-related
259 mortality [31, 32]. While most cases of HIV-associated cryptococcal meningitis occur when CD4
260 T-cell counts drop below 100 cells/ μ L, approximately 10-20% of cryptococcosis occurs at higher
261 CD4 T-cell counts [32]. Higher CD4 T-cell counts are more frequently associated with altered
262 mental status and lower CSF burden of *Cryptococcus* [32]. Despite low median CD4 T-cell

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Kasibante CSF Protein in Cryptococcosis

263 counts in both CSF protein groups, corresponding to advanced HIV disease, individuals with
264 CSF protein ≥ 100 mg/dL had a statistically significant higher baseline CD4 T-cell count,
265 suggesting the possibility of an enhanced T-cell mediated immune response to *Cryptococcus*.
266 The enhanced T-cell mediated immune response and presence of increased levels of CSF
267 cytokines when CSF protein ≥ 100 mg/dL may explain the resulting lower baseline CSF fungal
268 burden, higher percentage of sterile cultures at 2 weeks, as well as the occurrence of altered
269 mental status and seizures at baseline. Ultimately, additional research is needed to thoroughly
270 investigate the functionality of CD4 T-cells in the context CSF protein in cryptococcal
271 meningitis.

272 Despite the higher CSF white cell count, lower CSF fungal burden, and higher levels of
273 CSF cytokines in individuals with a CSF protein ≥ 100 mg/dL, the survival advantage was
274 negated after adjusting for established risk factors of cryptococcal mortality. Notably, altered
275 mental status was observed in 46% of individuals with a CSF protein ≥ 100 mg/dL at baseline.
276 We have previously demonstrated that altered mental status in cryptococcosis is most likely
277 associated with a dysfunctional host immune response [33]. Here, we demonstrate a robust
278 inflammatory response in individuals with CSF protein ≥ 100 mg/dL, characterized by a
279 predominantly pro-inflammatory cytokine response skewed toward type-1 T helper cell and
280 type-3 immune responses. Taken together, our findings suggest that individuals with
281 cryptococcal meningitis presenting with altered mental status and a baseline CSF protein ≥ 100
282 mg/dL may be exhibiting a robust inflammatory response leading to neurologic deterioration and
283 death [21] . This is consistent with the damage-response framework proposed by Pirofski and
284 Casadevall, a strong host-mediated inflammatory response during cryptococcal infection can
285 inflict host damage, neurological impairment, and death [34].

Kasibante CSF Protein in Cryptococcosis

286 Our study has several limitations. Our study population consisted of only people living
287 with HIV and hence may not be generalizable to cases of non-HIV associated cryptococcal
288 meningitis. We measured CSF cytokine levels only at baseline, and inflammation changes over
289 time [35]. We recognize that cytokine levels can fluctuate over time, and we may not have
290 captured the complete dynamics of the immune response in cryptococcal meningitis. We did not
291 assess serum protein levels, which would have allowed for a better evaluation of the CSF to
292 serum protein ratio. The ratio provides information about the permeability and integrity of the
293 blood-brain barrier during meningeal inflammation, which would affect CSF protein level [36].
294 Lastly, our study combined data from two separate clinical trials which may affect the internal
295 validity of the study.

296 In conclusion, we have demonstrated that baseline CSF protein levels can serve as a
297 surrogate marker of immune activation in cryptococcal meningitis and provide valuable
298 information on disease severity. Individuals with CSF protein ≥ 100 mg/dL exhibited a more
299 robust immune response against cryptococcal disease, as indicated by a lower CSF fungal burden
300 at baseline and a higher percentage of sterile CSF cultures at day 14. On the other hand,
301 individuals with a CSF protein < 100 mg/dL, particularly those not on ART, demonstrated a
302 deficient or absent cell-mediated immune response, manifested by a higher CSF fungal burden at
303 baseline, lower CSF white blood cell count, fewer sterile cultures at day 14, and higher 18-week
304 mortality. Further studies are warranted to investigate the potential of CSF protein levels as a
305 rapid predictive tool for identifying individuals who would benefit from targeted
306 immunomodulatory therapy to either dampen an exaggerated immune response or augment a
307 deficient immune response.

308

309 **Acknowledgements.**

310 ASTRO-cm and AMBITION-cm study Team Members. Reuben Kiggundu, Andrew
311 Akampurira, Paul Kirumira, Jane Francis Ndyetukira, Cynthia Ahimbisibwe, Florence Kugonza,
312 Carolyn Namuju, Alisat Sadiq, Tadeo Kiiza Kandole, Tony Luggya, Julian Kaboggoza, Eva
313 Laker, Alice Namudde, Sarah Lofgren, Richard Kwizera, Irene Rwomushana, Mike Ssemusu,
314 Joan Rukundo, James Mwesigye, Kirsten Nielsen, Anna Stadelman, Ananta S. Bangdiwala,
315 David Lawrence and Nabila Youssouf.

316

317 **Financial support.**

318 This work was supported by the National Institute of Neurologic Diseases and Stroke
319 (R01NS086312, K23NS122601); the Fogarty International Center (K01TW010268,
320 R25TW009345); the National Institute of Allergy and Infectious Diseases (T32AI055433);
321 United Kingdom Medical Research Council / DfID / Wellcome Trust Global Clinical Trials
322 (grant numbers M007413/1, MR/P006922/1); Grand Challenges Canada (S4-0296-01); and the
323 European and Developing Countries Clinical Trials Partnership (EDCTP) (TRIA2015-1092)
324 with assistance from the Swedish International Development Cooperation Agency (SIDA), the
325 U.K. Department of Health and Social Care, the U.K. Foreign Commonwealth and Development
326 Office, and the U.K. Medical Research Council.

327

328 **Potential conflicts of interest.**

329 All authors: no reported conflicts of interest.

330 **References.**

- 331 1. UNAIDS. Global HIV & AIDS statistics — Fact sheet.
332 <https://www.unaids.org/en/resources/fact-sheet> **2021**.
- 333 2. Rajasingham R, Govender NP, Jordan A, Loyse A, Shroufi A, Denning DW, et al. The
334 global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling
335 analysis. *Lancet Infect Dis* **2022**; 22: 1748-55.
- 336 3. Jarvis JN, Lawrence DS, Meya DB, Kagimu E, Kasibante J, Mpoza E, et al. Single-Dose
337 Liposomal Amphotericin B Treatment for Cryptococcal Meningitis. *N Engl J Med* **2022**;
338 386: 1109-20.
- 339 4. Rhein J, Huppler Hullsiek K, Tugume L, Nuwagira E, Mpoza E, Evans EE, et al.
340 Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-
341 controlled, double-blind phase 3 trial. *Lancet Infect Dis* **2019**; 19: 843-51.
- 342 5. Schilde LM, Kösters S, Steinbach S, Schork K, Eisenacher M, Galozzi S, et al. Protein
343 variability in cerebrospinal fluid and its possible implications for neurological protein
344 biomarker research. *PLoS One* **2018**; 13: e0206478.
- 345 6. Seehusen DA, Reeves MM, Fomin DA. Cerebrospinal fluid analysis. *Am Fam Physician*
346 **2003**; 68: 1103-8.
- 347 7. Huang L, Ye H, Qu J, Liu Y, Zhong C, Tang G, et al. Analysis of cerebrospinal fluid
348 protein concentrations of patients with cryptococcal meningitis treated with antifungal
349 agents. *BMC Infect Dis* **2015**; 15: 333.
- 350 8. Diamond RD, Bennett JE. Prognostic factors in cryptococcal meningitis. A study in 111
351 cases. *Ann Intern Med* **1974**; 80: 176-81.
- 352 9. Qu J, Jiang J, Lv X. The utility of cerebrospinal fluid white cell count during the
353 prognostic assessment for cryptococcal meningitis patients: a retrospective study. *BMC*
354 *Infect Dis* **2020**; 20: 571.
- 355 10. Bicanic T, Brouwer AE, Meintjes G, Rebe K, Limmathurotsakul D, Chierakul W, et al.
356 Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with
357 cryptococcal meningitis undergoing serial lumbar punctures. *AIDS* **2009**; 23: 701-6.
- 358 11. Boulware DR, Bonham SC, Meya DB, Wiesner DL, Park GS, Kambugu A, et al. Paucity
359 of Initial Cerebrospinal Fluid Inflammation in Cryptococcal Meningitis Is Associated
360 with Subsequent Immune Reconstitution Inflammatory Syndrome. *Journal of Infectious*
361 *Diseases* **2010**; 202: 962-70.
- 362 12. Jarvis JN, Bicanic T, Loyse A, Namarika D, Jackson A, Nussbaum JC, et al.
363 Determinants of mortality in a combined cohort of 501 patients with HIV-associated
364 Cryptococcal meningitis: implications for improving outcomes. *Clin Infect Dis* **2014**; 58:
365 736-45.
- 366 13. Lawrence DS, Youssouf N, Molloy SF, Alanio A, Alufandika M, Boulware DR, et al.
367 AMBIsome Therapy Induction Optimisation (AMBITION): High Dose AmBisome for

Kasibante CSF Protein in Cryptococcosis

- 368 Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a
369 Phase 3 Randomised Controlled Non-Inferiority Trial. *Trials* **2018**; 19: 649.
- 370 14. Williams DA, Kiiza T, Kwizera R, Kiggundu R, Velamakanni S, Meya DB, et al.
371 Evaluation of fingerstick cryptococcal antigen lateral flow assay in HIV-infected persons:
372 a diagnostic accuracy study. *Clin Infect Dis* **2015**; 61: 464-7.
- 373 15. Boulware DR, Rolfes MA, Rajasingham R, von Hohenberg M, Qin Z, Taseera K, et al.
374 Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser
375 thermal contrast. *Emerg Infect Dis* **2014**; 20: 45-53.
- 376 16. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate - a Practical and
377 Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society Series B-*
378 *Statistical Methodology* **1995**; 57: 289-300.
- 379 17. Pullen MF, Hullsiek KH, Rhein J, Musubire AK, Tugume L, Nuwagira E, et al.
380 Cerebrospinal Fluid Early Fungicidal Activity as a Surrogate Endpoint for Cryptococcal
381 Meningitis Survival in Clinical Trials. *Clin Infect Dis* **2020**; 71: e45-e9.
- 382 18. Scriven JE, Graham LM, Schutz C, Scriba TJ, Wilkinson KA, Wilkinson RJ, et al. The
383 CSF Immune Response in HIV-1-Associated Cryptococcal Meningitis: Macrophage
384 Activation, Correlates of Disease Severity, and Effect of Antiretroviral Therapy. *J Acquir*
385 *Immune Defic Syndr* **2017**; 75: 299-307.
- 386 19. Jarvis JN, Casazza JP, Stone HH, Meintjes G, Lawn SD, Levitz SM, et al. The phenotype
387 of the Cryptococcus-specific CD4+ memory T-cell response is associated with disease
388 severity and outcome in HIV-associated cryptococcal meningitis. *J Infect Dis* **2013**; 207:
389 1817-28.
- 390 20. Jarvis JN, Meintjes G, Bicanic T, Buffa V, Hogan L, Mo S, et al. Cerebrospinal fluid
391 cytokine profiles predict risk of early mortality and immune reconstitution inflammatory
392 syndrome in HIV-associated cryptococcal meningitis. *PLoS Pathog* **2015**; 11: e1004754.
- 393 21. Neal LM, Xing E, Xu J, Kolbe JL, Osterholzer JJ, Segal BM, et al. CD4(+) T Cells
394 Orchestrate Lethal Immune Pathology despite Fungal Clearance during *Cryptococcus*
395 *neoformans* Meningoencephalitis. *mBio* **2017**; 8: pii: e01415-17.
- 396 22. Geiser T, Dewald B, Ehrenguber MU, Clark-Lewis I, Baggiolini M. The interleukin-8-
397 related chemotactic cytokines GRO alpha, GRO beta, and GRO gamma activate human
398 neutrophil and basophil leukocytes. *J Biol Chem* **1993**; 268: 15419-24.
- 399 23. Takatsu K, Nakajima H. IL-5 and eosinophilia. *Curr Opin Immunol* **2008**; 20: 288-94.
- 400 24. Zenobia C, Hajishengallis G. Basic biology and role of interleukin-17 in immunity and
401 inflammation. *Periodontol 2000* **2015**; 69: 142-59.
- 402 25. Aziz N, Detels R, Chang LC, Butch AW. Macrophage Inflammatory Protein-3 Alpha
403 (MIP-3alpha)/CCL20 in HIV-1-Infected Individuals. *J AIDS Clin Res* **2016**; 7.
- 404 26. Che YM, Zhang Y, Li M, Li XP, Zhang LL. In vitro and in vivo effect of PD-1/PD-L1
405 blockade on microglia/macrophage activation and T cell subset balance in cryptococcal
406 meningitis. *J Cell Biochem* **2018**; 119: 3044-57.


Kasibante CSF Protein in Cryptococcosis

- 407 27. Malyak M, Smith MF, Jr., Abel AA, Hance KR, Arend WP. The differential production
408 of three forms of IL-1 receptor antagonist by human neutrophils and monocytes. *J*
409 *Immunol* **1998**; 161: 2004-10.
- 410 28. Ross SH, Cantrell DA. Signaling and Function of Interleukin-2 in T Lymphocytes. *Annu*
411 *Rev Immunol* **2018**; 36: 411-33.
- 412 29. Ma LL, Wang CLC, Neely GG, Epelman S, Krensky AM, Mody CH. NK cells use
413 perforin rather than granulysin for anticryptococcal activity. *Journal of Immunology*
414 **2004**; 173: 3357-65.
- 415 30. Zheng CF, Ma LL, Jones GJ, Gill MJ, Krensky AM, Kubes P, Mody CH. Cytotoxic
416 CD4+ T cells use granulysin to kill *Cryptococcus neoformans*, and activation of this
417 pathway is defective in HIV patients. *Blood* **2007**; 109: 2049-57.
- 418 31. Rohatgi S, Pirofski LA. Host immunity to *Cryptococcus neoformans*. *Future Microbiol*
419 **2015**; 10: 565-81.
- 420 32. Tugume L, Rhein J, Hullsiek KH, Mpoza E, Kiggundu R, Ssebambulidde K, et al. HIV-
421 Associated Cryptococcal Meningitis Occurring at Relatively Higher CD4 Counts.
422 *Journal of Infectious Diseases* **2019**; 219: 877-83.
- 423 33. Lofgren S, Hullsiek KH, Morawski BM, Nabeta HW, Kiggundu R, Taseera K, et al.
424 Differences in Immunologic Factors Among Patients Presenting with Altered Mental
425 Status During Cryptococcal Meningitis. *Journal of Infectious Diseases* **2017**; 215: 693-7.
- 426 34. Pirofski LA, Casadevall A. The damage-response framework of microbial pathogenesis
427 and infectious diseases. *Adv Exp Med Biol* **2008**; 635: 135-46.
- 428 35. Scriven JE, Rhein J, Hullsiek KH, von Hohenberg M, Linder G, Rolfes MA, et al. Early
429 ART After Cryptococcal Meningitis Is Associated With Cerebrospinal Fluid Pleocytosis
430 and Macrophage Activation in a Multisite Randomized Trial. *J Infect Dis* **2015**; 212: 769-
431 78.
- 432 36. Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, et al. Clinical and
433 Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients
434 with B-cell Acute Lymphoblastic Leukemia. *Cancer Discov* **2018**; 8: 958-71.
- 435

Figure 1a

medRxiv preprint doi: <https://doi.org/10.1101/2023.12.10.23299793>; this version posted December 12, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



| | | | | | | | | | |
|-----------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Number at Risk: | 641 | 481 | 435 | 406 | 382 | 372 | 241 | 207 | 194 |
| | 249 | 199 | 181 | 173 | 166 | 161 | 109 | 98 | 97 |

Figure 1a

Figure 1b

medRxiv preprint doi: <https://doi.org/10.1101/2023.12.10.23299793>; this version posted December 12, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).




Figure 1b